Search

Displaying results 3221 - 3230 of 7284 in total
  1. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  2. Drug

    Bempedoic acid

    go.drugbank.com/drugs/DB11936
    ApprovedInvestigational

    [L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. … High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events.

  3. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.

  4. Drug

    Glyburide

    go.drugbank.com/drugs/DB01016
    ApprovedInvestigational

    [A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120] … Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II.

  5. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals. … [L31198] While previously administered once monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and without the need for an oral lead-in

  6. Drug

    Fenofibric acid

    go.drugbank.com/drugs/DB13873
    ApprovedInvestigational

    Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia.

  7. Drug

    Gestaclone

    go.drugbank.com/drugs/DB21090
    Experimental

    Gestaclone is a small molecule drug. The usage of the INN stem '-clone' in the name indicates that Gestaclone is a hypnotic tranquillizer. Gestaclone has a monoisotopic molecular weight of 370.17 Da.

  8. Drug

    Dihydrostreptomycin

    go.drugbank.com/drugs/DB11512
    ApprovedVet approvedWithdrawn

    The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]

    Synonyms: N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-a-L-glucopyranosyl]-3-C-(hydroxymethyl)-a-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine
  9. Drug

    Betoxycaine

    go.drugbank.com/drugs/DB19475
    Experimental

    Betoxycaine is a small molecule drug. The usage of the INN stem '-caine' in the name indicates that Betoxycaine is a local anaesthetic. Betoxycaine has a monoisotopic molecular weight of 352.24 Da.

  10. Drug

    Motrazepam

    go.drugbank.com/drugs/DB19799
    Experimental

    Motrazepam is a small molecule drug. The usage of the INN stem '-azepam' in the name indicates that Motrazepam is a diazepam derivative. Motrazepam has a monoisotopic molecular weight of 325.11 Da.